STOCKS | Sino Biopharm Says Subsidiary Signs Exclusive License Deal With AstraZeneca
2026-07-08 02:22:20
Sino Biopharmaceutical (1177) said its subsidiary Chia Tai Tianqing has signed an exclusive licensing agreement with AstraZeneca for the group’s self-developed PDE3/4 inhibitor, code-named TQC3721, according to Ming Pao.
Disclaimer:
1. The information provided does not constitute investment advice. Investors should make independent decisions and bear all risks themselves.
2. The copyright of this content belongs to the original author. The views expressed herein are solely those of the author and do not represent the stance or position of this website.
Previous article：
股票市场 | 极兔速递：二季度包裹量同比增24.2%至91.76亿件
